AstraZeneca Results Presentation Deck
Alexion: recent US FTC clearance milestone
Acquisition logic, rationale and highlights unchanged
Compelling scientific complementarity and synergy, e.g.
Pipeline boosted with 11 molecules across 20+ programmes
Combination of two science- and patient-centric organisations
Further-sustained, industry-leading revenue growth, e.g.
Double-digit average annual revenue growth through 2025
25
●
●
Improved profitability and strengthened cash flow
Core operating margin significantly enhanced in the short term, and with continued margin expansion thereafter
Synergies c.$500m per year by the end of the third year following completion
●
●
●
ALEXION
●
TRANSITION PLANNING TEAM —
Double-digit percentage core EPS accretion anticipated in the first three years following completion
Strong cash flow, rapid debt deleveraging with an ambition to increase the dividend
Strong, investment-grade credit rating to provide strategic and financial flexibility
ASTRAZENECA
Significant regulatory progress; several important competition clearances obtained
Shareholder vote 11 May 2021
Source: 12 December 2020 webinar and conference call for investors and analysts on the proposed Alexion acquisition. Targets provided above are aspirational only and should not be considered formal guidance. For details, including legal disclaimer, please visit:
https://www.astrazeneca.com/investor-relations/astrazeneca-to-acquire-alexion.html. For a complete list of competition authority clearances, please visit: https://www.astrazeneca.com/investor-relations/astrazeneca-to-acquire-alexion.html#table.
BView entire presentation